FDA Approves Mirtazapine Application ANDA220104 from Micro Labs
The FDA has approved the ANDA220104 application for Mirtazapine submitted by Micro Labs.
Asset / Drug
Drug and asset intelligence for Mirtazapine with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
A clinical trial is evaluating Mirtazapine's efficacy in reducing methamphetamine use among opioid use disorder patients receiving medication-assisted treatment.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.